87 related articles for article (PubMed ID: 27343834)
1. Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles.
Tougan T; Ito K; Palacpac NM; Egwang TG; Horii T
Parasitol Int; 2016 Oct; 65(5 Pt A):455-8. PubMed ID: 27343834
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.
Palacpac NM; Ntege E; Yeka A; Balikagala B; Suzuki N; Shirai H; Yagi M; Ito K; Fukushima W; Hirota Y; Nsereko C; Okada T; Kanoi BN; Tetsutani K; Arisue N; Itagaki S; Tougan T; Ishii KJ; Ueda S; Egwang TG; Horii T
PLoS One; 2013; 8(5):e64073. PubMed ID: 23724021
[TBL] [Abstract][Full Text] [Related]
3. Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda.
Yagi M; Palacpac NM; Ito K; Oishi Y; Itagaki S; Balikagala B; Ntege EH; Yeka A; Kanoi BN; Katuro O; Shirai H; Fukushima W; Hirota Y; Egwang TG; Horii T
Sci Rep; 2016 Oct; 6():34363. PubMed ID: 27703240
[TBL] [Abstract][Full Text] [Related]
4. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
Horii T; Shirai H; Jie L; Ishii KJ; Palacpac NQ; Tougan T; Hato M; Ohta N; Bobogare A; Arakaki N; Matsumoto Y; Namazue J; Ishikawa T; Ueda S; Takahashi M
Parasitol Int; 2010 Sep; 59(3):380-6. PubMed ID: 20493274
[TBL] [Abstract][Full Text] [Related]
5. African-specific polymorphisms in
Arisue N; Palacpac NMQ; Ntege EH; Yeka A; Balikagala B; Kanoi BN; Bougouma EC; Tiono AB; Nebie I; Diarra A; Houard S; D'Alessio F; Leroy O; Sirima SB; Egwang TG; Horii T
Front Cell Infect Microbiol; 2022; 12():1058081. PubMed ID: 36590593
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.
Bougouma EC; Palacpac NMQ; Tiono AB; Nebie I; Ouédraogo A; Houard S; Yagi M; Coulibaly SA; Diarra A; Tougan T; Ouedraogo AZ; Soulama I; Arisue N; Yaro JB; D'Alessio F; Leroy O; Cousens S; Horii T; Sirima SB
Front Immunol; 2022; 13():978591. PubMed ID: 36119062
[TBL] [Abstract][Full Text] [Related]
7.
Tiono AB; Palacpac NMQ; Bougouma EC; Nebie I; Ouédraogo A; Houard S; Arisue N; D'Alessio F; Horii T; Sirima SB
Front Immunol; 2023; 14():1119820. PubMed ID: 36993981
[TBL] [Abstract][Full Text] [Related]
8. [Development and application of next generation SE36 malaria vaccine formulated with a novel adjuvant: approach to travelers' vaccine].
Tougan T; Ishii KJ; Horii T
Yakugaku Zasshi; 2013; 133(11):1153-7. PubMed ID: 24189556
[TBL] [Abstract][Full Text] [Related]
9. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
[TBL] [Abstract][Full Text] [Related]
10. First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
Ezoe S; Palacpac NMQ; Tetsutani K; Yamamoto K; Okada K; Taira M; Nishida S; Hirata H; Ogata A; Yamada T; Yagi M; Edula JR; Oishi Y; Tougan T; Ishii KJ; Myoui A; Horii T
Vaccine; 2020 Oct; 38(46):7246-7257. PubMed ID: 33012605
[TBL] [Abstract][Full Text] [Related]
11. Association of naturally acquired IgG antibodies against Plasmodium falciparum serine repeat antigen-5 with reduced placental parasitemia and normal birth weight in pregnant Ugandan women: a pilot study.
Owalla TJ; Palacpac NM; Shirai H; Horii T; Egwang TG
Parasitol Int; 2013 Jun; 62(3):237-9. PubMed ID: 23395684
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
Ouédraogo A; Bougouma EC; Palacpac NMQ; Houard S; Nebie I; Sawadogo J; Berges GD; Soulama I; Diarra A; Hien D; Ouedraogo AZ; Konaté AT; Kouanda S; Myoui A; Ezoe S; Ishii KJ; Sato T; D'Alessio F; Leroy O; Tiono AB; Cousens S; Horii T; Sirima SB
Front Immunol; 2023; 14():1267372. PubMed ID: 37908361
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.
Palacpac NM; Arisue N; Tougan T; Ishii KJ; Horii T
Vaccine; 2011 Aug; 29(35):5837-45. PubMed ID: 21718740
[TBL] [Abstract][Full Text] [Related]
14. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children.
Okech B; Mujuzi G; Ogwal A; Shirai H; Horii T; Egwang TG
Am J Trop Med Hyg; 2006 Feb; 74(2):191-7. PubMed ID: 16474069
[TBL] [Abstract][Full Text] [Related]
15. [Malaria vaccine].
Horii T
Nihon Rinsho; 2008 Oct; 66(10):1990-8. PubMed ID: 18939502
[TBL] [Abstract][Full Text] [Related]
16. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.
Yagi M; Bang G; Tougan T; Palacpac NM; Arisue N; Aoshi T; Matsumoto Y; Ishii KJ; Egwang TG; Druilhe P; Horii T
PLoS One; 2014; 9(6):e98460. PubMed ID: 24886718
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent carriage of alleles and haplotypes of Plasmodium falciparum sera5, eba-175, and csp in a region of intense malaria transmission in Uganda.
Agwang C; Erume J; Okech B; Olobo J; Egwang TG
Malar J; 2020 Oct; 19(1):361. PubMed ID: 33032613
[TBL] [Abstract][Full Text] [Related]
18. Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals.
Zhang Q; Xue X; Xu X; Wang C; Chang W; Pan W
J Clin Immunol; 2009 Jul; 29(4):454-60. PubMed ID: 19247821
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
20. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
